TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10344293

Group type: EXPERIMENTAL
Intervention: Short-term hypoxia (100% N2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Short-term hypoxia (100% N2) combined with hypercapnia (95% N2-5% CO2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Short-term hypercapnia (95% N2-5% CO2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 8
Study: 7573260

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg twice a day, slow-release capsules)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 54
Study: 2406228

Group type: EXPERIMENTAL
Intervention: Positive Radiation Group (PRG): further irradiation to a total dose of 90 Gy by the cone‐down and assault technique.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Positive Observation Group (POG): no further irradiation, followed periodically.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Negative Observation Group (NOG): pathology negative patients followed periodically.
Number of subjects: 78
Study: 6768079

Group type: EXPERIMENTAL
Intervention: Apomorphine (continuous IV infusion for 180-240 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-infusion period (240 min after apomorphine infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol or sulpiride (dopamine receptor blocking agents)
Number of subjects: 0
Study: 6626789

Group type: EXPERIMENTAL
Intervention: Elated mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depressed mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0
Study: 30755129

Group type: EXPERIMENTAL
Intervention: Peer specialist services
Number of subjects: 71
Study: 29371007

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 178
Study: 26275929

Group type: EXPERIMENTAL
Intervention: Bleaching enzyme-based toothpaste (White Kin(®))
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 48
Study: 24787908

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (800,000 IU, 4000 IU daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21434968

Group type: EXPERIMENTAL
Intervention: Ideal body image (IBI)
Number of subjects: 402
Study: 19857313

Group type: EXPERIMENTAL
Intervention: Antibiotics for mild diverticulitis
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: Elective surgical resection for recurrent diverticulitis
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: Laparoscopic peritoneal lavage for purulent peritonitis
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: Resection with primary anastomosis for Hinchey III or IV diverticulitis
Number of subjects: 14000
Study: 17481486

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 930

Group type: COMPARATOR
Intervention: Surgical shunts
Number of subjects: 930
Study: 16351775

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup (20 mg elemental Fe twice daily)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 12438475

Group type: EXPERIMENTAL
Intervention: Two weeks of prednisolone 20 mg daily followed by two weeks of prednisolone 10 mg daily (n = 53)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Two weeks of prednisolone 20 mg daily and two weeks of placebo (n = 56)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Follow up electrodiagnosis
Number of subjects: 109
Study: 10349956

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 141

Group type: COMPARATOR
Intervention: Bacitracin
Number of subjects: 141
Study: 9389675

Group type: EXPERIMENTAL
Intervention: Urodilatin infusion (40 ng / kg bw / min for 6 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2025672

Group type: EXPERIMENTAL
Intervention: Invitations to attend screening (n = 163)
Number of subjects: 243

Group type: COMPARATOR
Intervention: No invitations (Control group, n = 80)
Number of subjects: 243
Study: 7262217

Group type: EXPERIMENTAL
Intervention: Hand trajectory and joint angular curves observed during pointing movements.
Number of subjects: 0
Study: 31794968

Group type: EXPERIMENTAL
Intervention: Prompt Mental Health Care (PMHC)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 681
Study: 31338716

Group type: EXPERIMENTAL
Intervention: Peer-delivered Seeking Safety (SS)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Clinician-delivered Seeking Safety (SS)
Number of subjects: 291
Study: 28170279

Group type: EXPERIMENTAL
Intervention: 74 g raisins
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 g glucose
Number of subjects: 10
Study: 25579717

Group type: EXPERIMENTAL
Intervention: Salacia oblonga in non-diabetic CKD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Salacia oblonga in diabetic CKD
Number of subjects: 60
Study: 24016832

Group type: EXPERIMENTAL
Intervention: Adaptive Statistical Iterative Reconstruction (ASIR) at 275 mAs
Number of subjects: 66

Group type: COMPARATOR
Intervention: Filtered-Back-Projection (FBP) at 340 mAs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Filtered-Back-Projection (FBP) at 275 mAs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Adaptive Statistical Iterative Reconstruction (ASIR) at 340 mAs
Number of subjects: 66
Study: 22287379

Group type: EXPERIMENTAL
Intervention: Point-of-care computed tomography (POC-CT) at the initial visit followed by medical therapy based on CT results (pre-CT group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empiric medical therapy (EMT) followed by POC posttreatment CT if symptoms persisted (EMT group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empiric medical therapy (EMT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Point-of-care computed tomography (POC-CT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall prescriptions costs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall number of otolaryngology visits
Number of subjects: 40
Study: 19560388

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) using GlucoDay system for 48 hours
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual self-monitoring of blood glucose (SMBG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) in T2D patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) in T1D patients
Number of subjects: 48
Study: 17880502

Group type: EXPERIMENTAL
Intervention: Topical application of 5% ALA solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical application of 10% ALA solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical application of 0.5%, 1%, 3%, 5%, or 10% ALA solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical application of ALA solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DNA typing analysis
Number of subjects: 60
Study: 15326078

Group type: EXPERIMENTAL
Intervention: 8-mm-tip catheter for short CTI (≤35 mm)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Cooled-tip catheter for long CTI (>35 mm)
Number of subjects: 185

Group type: COMPARATOR
Intervention: 8-mm-tip catheter for long CTI (>35 mm)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Comparison of 8-mm-tip and cooled-tip catheters for long CTI (>35 mm)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Patients with short and straight CTIs
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Pouch-like recesses and concave characteristics
Number of subjects: 185
Study: 12821038

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 9933475

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (500 mg/day of elemental calcium and 700 IU/day of cholecalciferol)
Number of subjects: 402
Study: 7480474

Group type: EXPERIMENTAL
Intervention: Genetic method of transmission, little suffering
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Genetic method of transmission, much suffering
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Contagious method of transmission, little suffering
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Contagious method of transmission, much suffering
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Infectious method of transmission, little suffering
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Infectious method of transmission, much suffering
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Population likely to become ill: primarily marginal persons
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Population likely to become ill: anyone
Number of subjects: 222
Study: 2196962

Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline
Number of subjects: 261

Group type: COMPARATOR
Intervention: 300 mg doxycycline
Number of subjects: 261

Group type: COMPARATOR
Intervention: Standard tetracycline
Number of subjects: 261
Study: 7356102

Group type: EXPERIMENTAL
Intervention: Chemotherapy with 5‐fluorouracil, vinblastine, and cyclophosphamide
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 53
Study: 31738468

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (20 min exercise 20% above lactate threshold)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (20 min exercise 20% below lactate threshold)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (seated rest)
Number of subjects: 33
Study: 29884572

Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (70% ethanol)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (heparinised saline)
Number of subjects: 94
Study: 26449551

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 32
Study: 24000106

Group type: EXPERIMENTAL
Intervention: Weaning from a convective incubator at 1,500 g body weight
Number of subjects: 21

Group type: COMPARATOR
Intervention: Weaning from a convective incubator at 1,600 g body weight (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (1,500 g and 1,600 g)
Number of subjects: 21
Study: 22414624

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet (GI=47)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High Glycemic Index (HGI) diet (GI=90)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both LGI and HGI diets
Number of subjects: 50
Study: 20506226

Group type: EXPERIMENTAL
Intervention: Intravenous autologous ex vivo cultured MSCs (MSC group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no MSC treatment)
Number of subjects: 52
Study: 18302840

Group type: EXPERIMENTAL
Intervention: Community-based educational program for asthma patients
Number of subjects: 50
Study: 15820237

Group type: EXPERIMENTAL
Intervention: Bupropion XL (up to 450 mg/day)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 12094199

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-PTCA CTFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTFC/MLD ratio
Number of subjects: 0
Study: 10969091

Group type: EXPERIMENTAL
Intervention: Intervention (leaflet and counseling to limit pacifier use)
Number of subjects: 484

Group type: COMPARATOR
Intervention: No continuous pacifier use
Number of subjects: 484
Study: 8707164

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins
Number of subjects: 0
Study: 1855746

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (150 units)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No hyaluronidase
Number of subjects: 20
Study: 6133303

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beta-blockade
Number of subjects: 33
Study: 31152332

Group type: EXPERIMENTAL
Intervention: Anti-CdtB testing after epitope stabilization
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Anti-vinculin testing after epitope stabilization
Number of subjects: 131
Study: 29724865

Group type: EXPERIMENTAL
Intervention: Intravenous bolus administration of 400 µg TRH
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (2 mL saline)
Number of subjects: 16
Study: 27187893

Group type: EXPERIMENTAL
Intervention: Varenicline (active pill plus placebo patch)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Nicotine patch (active patch plus placebo pill)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Placebo (placebo pill plus placebo patch)
Number of subjects: 1246
Study: 24756119

Group type: EXPERIMENTAL
Intervention: Multipurpose solution
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide care system
Number of subjects: 218

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 218
Study: 22389136

Group type: EXPERIMENTAL
Intervention: Infrahepatic IVC clamping
Number of subjects: 192

Group type: COMPARATOR
Intervention: Low central venous pressure (CVP)
Number of subjects: 192
Study: 20634735

Group type: EXPERIMENTAL
Intervention: Cold air running
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warm air running
Number of subjects: 12
Study: 17828765

Group type: EXPERIMENTAL
Intervention: 3-week intervention group instructed in cultivating sacred moments
Number of subjects: 73

Group type: COMPARATOR
Intervention: 3-week control group instructed in writing about daily activities
Number of subjects: 73
Study: 15668602

Group type: EXPERIMENTAL
Intervention: Fortified skimmed milk containing 1,200 mg of calcium and 5.7 microg of vitamin D (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fortified skimmed milk containing 900 mg of calcium and 5.7 microg of vitamin D (group B)
Number of subjects: 80
Study: 11881794

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg or 300 IU/kg, administered 3 times weekly for 28 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 37
Study: 9893315

Group type: EXPERIMENTAL
Intervention: qigong instruction by a qigong master
Number of subjects: 26

Group type: COMPARATOR
Intervention: sham master instruction
Number of subjects: 26
Study: 7731768

Group type: EXPERIMENTAL
Intervention: iohexol 140 mgI/ml
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: iohexol 240 mgI/ml
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: iohexol 300 mgI/ml
Number of subjects: 89
Study: 8460273

Group type: EXPERIMENTAL
Intervention: Needle drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional two-stage drainage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 3954920

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 76

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 76
Study: 31757838

Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide (EQW)
Number of subjects: 13844

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13844
Study: 30304127

Group type: EXPERIMENTAL
Intervention: Nanofilled self-adhesive light-cured protective coating (NPC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Petroleum jelly
Number of subjects: 32
Study: 26905020

Group type: EXPERIMENTAL
Intervention: Laparoscopic radio frequency ablation assisted tumor enucleation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Laparoscopic partial nephrectomy
Number of subjects: 89
Study: 25919902

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) at baseline and follow-up
Number of subjects: 389
Study: 23743576

Group type: EXPERIMENTAL
Intervention: Targeted training with no selective-attention demand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontargeted training with selective-attention demand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted training
Number of subjects: 0
Study: 21189381

Group type: EXPERIMENTAL
Intervention: Intravenous calcium/magnesium (1g calcium gluconate plus 1g magnesium sulfate pre‐ and post‐oxaliplatin)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intravenous calcium/magnesium
Number of subjects: 102
Study: 18650514

Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 602

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 602
Study: 16537737

Group type: EXPERIMENTAL
Intervention: 100% humidity (n = 46)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 40% humidity (optimally delivered placebo, n = 46)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Blow-by humidity (commonly used placebo, n = 48)
Number of subjects: 140
Study: 12524639

Group type: EXPERIMENTAL
Intervention: Temperament and Character Inventory (TCI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (29 women and their 27 fathers and 29 mothers)
Number of subjects: 28
Study: 10940745

Group type: EXPERIMENTAL
Intervention: Daily prednisone for 5 days during upper respiratory infection (URI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alternate‐day prednisone during URI
Number of subjects: 36
Study: 9737626

Group type: EXPERIMENTAL
Intervention: Ifetroban (250 mg daily)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 7920954

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine (0.15 mg/kg bolus followed by 0.15 mg/kg/hour for 12 hours)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bolus dosing of ranitidine (1 mg/kg, two doses 6 hours apart)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both regimens (continuous infusion and bolus dosing)
Number of subjects: 16
Study: 3401271

Group type: EXPERIMENTAL
Intervention: 10 mg bisacodyl solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dulcolax Dragees (2 x 5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dulcolax suppository (10 mg)
Number of subjects: 12
Study: 29442084

Group type: EXPERIMENTAL
Intervention: Herbal mouthwash
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorine dioxide mouthwash
Number of subjects: 40
Study: 28116300

Group type: EXPERIMENTAL
Intervention: understAID application (experimental group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 24411804

Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 20
Study: 22412178

Group type: EXPERIMENTAL
Intervention: Tonsillectomy and Adenoidectomy (T&A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tonsillectomy and Adenoidectomy with Pharyngoplasty (T&A + Pharyngoplasty)
Number of subjects: 60

Group type: COMPARATOR
Intervention: T&A
Number of subjects: 60

Group type: COMPARATOR
Intervention: T&A + Pharyngoplasty
Number of subjects: 60
Study: 20470848

Group type: EXPERIMENTAL
Intervention: ziprasidone 40 mg BID for 2 days, titrated up to 80 mg BID thereafter
Number of subjects: 54

Group type: COMPARATOR
Intervention: abrupt discontinuation of conventional antipsychotics
Number of subjects: 54

Group type: COMPARATOR
Intervention: fast taper-50% of conventional antipsychotic dosage on days 1 through 7, followed by discontinuation
Number of subjects: 54

Group type: COMPARATOR
Intervention: slow taper-100% of conventional antipsychotic dosage on days 1 and 2, followed by 50% on days 3 through 7, then discontinuation
Number of subjects: 54
Study: 18262432

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (100 mg/die) and atorvastatin (10 mg/die) combined treatment
Number of subjects: 52
Study: 16456725

Group type: EXPERIMENTAL
Intervention: Advice to eat fatty fish or fish oil capsules (DART)
Number of subjects: 5147

Group type: EXPERIMENTAL
Intervention: Advice to eat fatty fish (DART 2)
Number of subjects: 5147

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (DART 2)
Number of subjects: 5147

Group type: EXPERIMENTAL
Intervention: Fish or fish oil (DART 2)
Number of subjects: 5147
Study: 12208717

Group type: EXPERIMENTAL
Intervention: MRI of the optic nerve in ON patients
Number of subjects: 64

Group type: COMPARATOR
Intervention: MRI of the optic nerve in NAION patients
Number of subjects: 64
Study: 9697435

Group type: EXPERIMENTAL
Intervention: Intervention group (bereavement intervention)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 261
Study: 2628313

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 tablets (0.5-1.5 mg hourly)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous oxytocin (starting at 2 mU/min, max 64 mU/min)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 tablets
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 120
Study: 973938

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acebutolol and Practolol
Number of subjects: 6
Study: 30286004

Group type: EXPERIMENTAL
Intervention: Combined group (based on the combination of transverse diameter of cricoid ring and ED-LMB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: LMB group (based on ED-LMB alone)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 80

Group type: COMPARATOR
Intervention: LMB group
Number of subjects: 80
Study: 30468986

Group type: COMPARATOR
Intervention: Community-based cohort (CC) participants
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Hospital-based cohort (HC) participants
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Participants with alcohol use problems
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Participants with past suicide attempts
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Participants on psychiatric treatment
Number of subjects: 800
Study: 28966184

Group type: EXPERIMENTAL
Intervention: Training group (photography and self-assessment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study: 25908682

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498